# Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer

> **NCT00496795** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Bergen** · enrollment: 100 (estimated)

## Conditions studied

- Stage III Breast Cancer AJCC V7

## Interventions

- **OTHER:** epirubicin/docetaxel sequential

## Key facts

- **NCT ID:** NCT00496795
- **Lead sponsor:** University of Bergen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2007-09
- **Primary completion:** 2016-05
- **Final completion:** 2026-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496795, "Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00496795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*